Juvenile Xanthogranuloma: A Comparative Immunohistochemical Study of Factor XIIIa, CD11c, and CD4.
Journal
The American Journal of dermatopathology
ISSN: 1533-0311
Titre abrégé: Am J Dermatopathol
Pays: United States
ID NLM: 7911005
Informations de publication
Date de publication:
01 Jul 2022
01 Jul 2022
Historique:
pubmed:
23
3
2022
medline:
18
6
2022
entrez:
22
3
2022
Statut:
ppublish
Résumé
Juvenile xanthogranuloma is a group C and L non-Langerhans cell histiocytosis, and its cell of origin is still debatable. The expression of CD11c, a more recently described macrophage marker, and CD4 have not been studied comprehensively. This study aimed to expand immunophenotypic profile and hence our understanding of the origin of these lesions. The surgical pathology archive was searched for the cases with the pathologic diagnosis of "xanthogranuloma" from 1995 to 2019. Immunohistochemical (IHC) stains were performed for factor XIIIa, CD11c, and CD4. Morphologically, each lesion was classified into early classic, classic, or transitional subtypes. Seventy-seven cases were included with the median age of 7.8 years (male:female 1.3:1). Uniform positivity was noticed for CD4 (n = 77), CD68 (n = 37), CD163 (n = 5), and vimentin (n = 4) stains. Other stains included CD11c 75/77 (97.4%), factor XIIIa 71/76 (93.4%), S-100 protein 4/23 (17.4%), and CD1a 0/18 (0%). Despite insignificant association between morphologic subtype and main studied IHC stains, factor XIIIa reactivity was highest in transitional lesions and CD11c showed higher reactivity in early classic lesions. CD11c and CD4 are sensitive markers and showed promising results in the diagnosis of juvenile xanthogranuloma compared with factor XIIIa. Despite different reactivity of factor XIIIa and CD11c in various morphologic subtypes, such association was statistically insignificant.
Identifiants
pubmed: 35315372
doi: 10.1097/DAD.0000000000002185
pii: 00000372-202207000-00004
doi:
Substances chimiques
Biomarkers
0
S100 Proteins
0
Factor XIIIa
EC 2.3.2.13
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
493-498Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Hernandez-Martin A, Baselga E, Drolet BA, et al. Juvenile xanthogranuloma. J Am Acad Dermatol. 1997;36:355–367.
Dehner LP. Juvenile xanthogranulomas in the first two decades of life: a clinicopathologic study of 174 cases with cutaneous and extracutaneous manifestations. Am J Surg Pathol. 2003;27:579–593.
Janssen D, Harms D. Juvenile xanthogranuloma in childhood and adolescence: a clinicopathologic study of 129 patients from the kiel pediatric tumor registry. Am J Surg Pathol. 2005;29:21–28.
So N, Liu R, Hogeling M. Juvenile xanthogranulomas: examining single, multiple, and extracutaneous presentations. Pediatr Dermatol. 2020;37:637–644.
Samuelov L, Kinori M, Chamlin SL, et al. Risk of intraocular and other extracutaneous involvement in patients with cutaneous juvenile xanthogranuloma. Pediatr Dermatol. 2018;35:329–335.
Misery L, Boucheron S, Claudy AL. Factor XIIIa expression in juvenile xanthogranuloma. Acta Derm Venereol. 1994;74:43–44.
de Graaf JH, Timens W, Tamminga RY, et al. Deep juvenile xanthogranuloma: a lesion related to dermal indeterminate cells. Hum Pathol. 1992;23:905–910.
Sandell RF, Carter JM, Folpe AL. Solitary (juvenile) xanthogranuloma: a comprehensive immunohistochemical study emphasizing recently developed markers of histiocytic lineage. Hum Pathol. 2015;46:1390–1397.
Kraus MD, Haley JC, Ruiz R, et al. “Juvenile” xanthogranuloma: an immunophenotypic study with a reappraisal of histogenesis. Am J Dermatopathol. 2001;23:104–111.
Favara BE, Feller AC, Pauli M, et al. Contemporary classification of histiocytic disorders. The WHO committee on histiocytic/reticulum cell proliferations. Reclassification working group of the histiocyte society. Med Pediatr Oncol. 1997;29:157–166.
Paxton CN, O'Malley DP, Bellizzi AM, et al. Genetic evaluation of juvenile xanthogranuloma: genomic abnormalities are uncommon in solitary lesions, advanced cases may show more complexity. Mod Pathol. 2017;30:1234–1240.
Coffin CM. Fibrohistiocytic tumors. In: Coffin CM, Dehner LP, O'Shea PA, eds. Pediatric Soft Tissue Tumors. Baltimore, MD: Williams & Wilkins; 1997:179–213.
Burgdorf WH, Duray P, Rosai J. Immunohistochemical identification of lysozyme in cutaneous lesions of alleged histiocytic nature. Am J Clin Pathol. 1981;75:162–167.
Marrogi AJ, Dehner LP, Coffin CM, et al. Benign cutaneous histiocytic tumors in childhood and adolescence, excluding Langerhans' cell proliferations. A clinicopathologic and immunohistochemical analysis. Am J Dermatopathol. 1992;14:8–18.
Zelger B, Cerio R, Orchard G, et al. Juvenile and adult xanthogranuloma. A histological and immunohistochemical comparison. Am J Surg Pathol. 1994;18:126–135.
Sangueza OP, Salmon JK, White CR Jr, et al. Juvenile xanthogranuloma: a clinical, histopathologic and immunohistochemical study. J Cutan Pathol. 1995;22:327–335.
Nascimento AG. A clinicopathologic and immunohistochemical comparative study of cutaneous and intramuscular forms of juvenile xanthogranuloma. Am J Surg Pathol. 1997;21:645–652.
Newman CC, Raimer SS, Sanchez RL. Nonlipidized juvenile xanthogranuloma: a histologic and immunohistochemical study. Pediatr Dermatol. 1997;14:98–102.
Pouryazdanparast P, Yu L, Cutlan JE, et al. Diagnostic value of CD163 in cutaneous spindle cell lesions. J Cutan Pathol. 2009;36:859–864.
Sachdev R, Robbins J, Kohler S, et al. CD163 expression is present in cutaneous histiocytomas but not in atypical fibroxanthomas. Am J Clin Pathol. 2010;133:915–921.
Tidwell WJ, Googe PB. Tissue histiocyte reactivity with CD31 is comparable to CD68 and CD163 in common skin lesions. J Cutan Pathol. 2014;41:489–493.
Vanchinathan V, Mirzamani N, Kantipudi R, et al. The vascular marker CD31 also highlights histiocytes and histiocyte-like cells within cutaneous tumors. Am J Clin Pathol. 2015;143:177–185.
Sonoda T, Hashimoto H, Enjoji M. Juvenile xanthogranuloma clinicopathologic analysis and immunohistochemical study of 57 patients. Cancer. 1985;56:2280–2286.
Nguyen TT, Schwartz EJ, West RB, et al. Expression of CD163 (hemoglobin scavenger receptor) in normal tissues, lymphomas, carcinomas, and sarcomas is largely restricted to the monocyte/macrophage lineage. Am J Surg Pathol. 2005;29:617–624.
Song M, Kim SH, Jung DS, et al. Structural correlations between dermoscopic and histopathological features of juvenile xanthogranuloma. J Eur Acad Dermatol Venereol. 2011;25:259–263.
Muszbek L, Bereczky Z, Bagoly Z, et al. Factor XIII: a coagulation factor with multiple plasmatic and cellular functions. Physiol Rev. 2011;91:931–972.
Batista AC, Mendonça EF, Arantes Elias LS, et al. Nonlipidized juvenile xanthogranuloma: an unusual variant with a potential diagnostic pitfall. Int J Pediatr Otorhinolaryngol. 2012;76:295–299.
Marotta G, Raspadori D, Sestigiani C, et al. Expression of the CD11c antigen in B-cell chronic lymphoproliferative disorders. Leuk Lymphoma. 2000;37:145–149.
Johrens K, Happerfield LC, Brown JP, et al. A novel CD11c monoclonal antibody effective in formalin-fixed tissue for the diagnosis of hairy cell leukemia. Pathobiology. 2008;75:252–256.
Facchetti F, de Wolf-Peeters C, Mason DY, et al. Plasmacytoid T cells. Immunohistochemical evidence for their monocyte/macrophage origin. Am J Pathol. 1988;133:15–21.
Ferry JA, Harris NL. Plasmacytoid monocytes? Am J Clin Pathol. 1999;111:569.
Horny HP, Feller AC, Horst HA, et al. Immunocytology of plasmacytoid T cells: marker analysis indicates a unique phenotype of this enigmatic cell. Hum Pathol. 1987;18:28–32.
Swerdlow SH, Campo E, Harris NL. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008:439.
Vollenweider R, Lennert K. Plasmacytoid T-cell clusters in non-specific lymphadenitis. Virchows Arch B Cel Pathol Incl Mol Pathol. 1983;44:1–14.